At this workshop, clinicians active in the use of dendritic cells all expressed the need to have an available supply of interleukin (IL)-4. There was discussion that unless some institution, such as the National Cancer Institute of the U.S., took action, a stable commercial source of IL-4 might not be available in the future. The UICC leadership is currently looking into this matter. See also pages 2593–6.
No takes yet. Share an insight, caveat, or question.
Salgaller et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: